Research Associate/Fellow (Fixed-term)

CompanyUniversity of Nottingham

LocationNottingham, England, United Kingdom

Posted At12/30/2025

UK Visa Sponsorship Analytics

Analytics are greyed out due to low classification confidence (56.0%).

Occupation Type

Business and related research professionals

Occupation Code Skill LevelHigher Skilled

Sponsorship Salary Threshold

£41,700 (£21.38 per hour)

Standard minimum applies

Above analytics are generated algorithmically based on job titles and may not always be the same as the company's job classification. You can also check detailed occupation eligibility, and salary criteria on our UK Visa Eligible Occupations & Salary Thresholds page.

Disclaimer: Hunt UK Visa Sponsors aggregates job listings from publicly available sources, such as search engines, to assist with your job hunting. We do not claim affiliation with University of Nottingham. For the most up-to-date job details, please visit the official website by clicking "Apply Now."

Description

Area

Pharmacy

Location

University Park

Salary

£35,608 to £47,389 per annum, depending on skills and experience (minimum £35608 with relevant PhD). Salary progression beyond this scale is subject to performance.

Closing Date

Monday 02 February 2026

Reference

SCI283325

Research Associate/Fellow (Fixed term)

We are seeking a Research Associate/Fellow to join a multidisciplinary project funded by BBSRC. The overall collaborative project aim is to develop novel broad-spectrum antiviral compounds for use in animals and humans. The successful candidate will join highly motivated and well-funded research teams across the Schools of Pharmacy, Chemistry, and Veterinary Medicine and Science. The work is a collaboration between Dr Pavel Gershkovich, Prof Kin-Chow Chang, Dr Leah Goulding and Prof Chris Hayes.

A few years ago, we made a groundbreaking discovery of a plant-derived antiviral molecule, thapsigargin (TG) that is highly effective against major human and animal respiratory viruses: IAV, coronaviruses (including SARS-CoV-2) and respiratory syncytial virus (Al-Beltagi et al., 2021a; Al-Beltagi et al., 2021b; Goulding et al., 2020). Our findings that TG is a host-centric antiviral have been later corroborated by other groups (Shaban et al., 2022; Shaban et al., 2021). TG, a sesquiterpene lactone, is

an irreversible inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) pump whose inhibition prevents the replenishment of the ER Ca2+ pool, triggering (i) store operated calcium entry (SOCE) and (ii) ER stress and the unfolded protein response (UPR). Both processes culminate in a cellular antiviral state that blocks virus replication at multiple stages of virus life cycle.

Inspired by TG, we recently created a library (> 180) of second-generation semi-synthetic antivirals that can be structurally categorised into different compound families, exhibiting improved drug-like properties and safety whilst retaining antiviral efficacy against a range human and veterinary RNA viruses. A major problem of all existing virus-targeting antivirals, such as baloxavir, is the emergence of virus resistance which rapidly reduces their usefulness (Hayden et al., 2018; Leung et al., 2024; Uehara et al., 2020). The huge advantage of host-centric antivirals are much less susceptible to virus resistance since virus mutations cannot readily overcome its dependency on host cell functions.

The aims of this post are the in vitro and in vivo Drug Metabolism and Pharmacokinetics (DMPK) development of novel host-centric antiviral candidates.

This work will be based within the Division of Division of Molecular Therapeutics and Formulation, located within the School of Pharmacy and led by Dr Pavel Geshkovich. The candidate will be required to undertake research an

d day to day management of the biopharmaceutics, pharmacokinetics and drug delivery aspects of this research project, requiring a high degree of competence in one or more of the research areas listed. An aptitude for critical thinking and a flexible approach to collaborative research is vital.

Candidates should have, be close to completion of, or have equivalent experience, a PhD in Pharmacy, Pharmaceutical Sciences or related discipline, together with an interest in pharmacokinetics, bioanalysis and drug delivery.

This full-time (36.25 hours/week), fixed-term post is offered for an initial period of 1 year, starting on 1st March 2026 (or as soon as possible thereafter), with a potential 1 year extension (total 2 years), subject to satisfactory progress. Job share arrangements may be considered.

For informal enquiries, please contact: Dr Pavel Gershkovich ( pavel.gershkovich@nottingham.ac.uk ) Please note applications sent directly to this email address will not be accepted.

Email details to a friend

Apply Online

Further details:

Job Description/Role Profile

Our university is a supportive, inclusive, caring and positive community. We welcome those of different cultures, ethnicities and beliefs – indeed this very diversity is vital to our success, it is fundamental to our values and enriches life on campus. Visit our Equality, Diversity and Inclusion website.

We are proud to be

a Disability Confident Employer (Level 2) employer . Increasing the diversity of our community is extremely important to us and we are committed to the aims of Disability Confident Scheme.

We are the first university to have achieved Athena Swan Gold Award .

To help you succeed, we published Candidate Guidance to provide support on the application and interview process.

Discover our benefits, visit Your Benefits website.

We welcome applications from UK, Europe and worldwide and aim to make your move to the UK as smooth as possible. Visit the Moving to Nottingham page for details.

Your application will be considered on an equal basis, subject to the relevant permission to work in the UK as set out by UK Visas & Immigration .

View All Vacancies

View Previous List